In a study on patients with type 2 diabetes mellitus (T2DM), inhibition of the rennin-angiotensin–aldosterone system using an angiotensin converting enzyme (ACE) inhibitor or blocking the effect of angiotensin II through using an angiotensin receptor blocker decreased the progression from normoalbuminuria to microalbuminuria[12-19] and slowed the development of end-stage renal disease (ESRD)[15-20]. The gene discussed is ACE; the disease is type 2 diabetes mellitus.